Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

NCT01519284 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: BIA 9-1067 5 mg
DRUG: Entacapone
DRUG: Placebo
DRUG: levodopa/carbidopa
DRUG: BIA 9-1067 15 mg
DRUG: BIA 9-1067 30 mg

Sponsor

Bial - Portela C S.A.